Royalty Pharma Buys J&J Tremfya Royalties for $500M

TL;DR

Royalty Pharma just dropped $500M on J&J's Tremfya royalties - big move for their portfolio!

AI Summary

On June 17, 2024, Royalty Pharma plc announced the closing of its acquisition of a portion of the future royalty rights on Tremfya (guselkumab) from Johnson & Johnson for an upfront payment of $500 million. The agreement also includes potential milestone payments of up to $50 million. This acquisition is expected to enhance Royalty Pharma's diversified portfolio of royalty assets.

Why It Matters

This strategic acquisition diversifies Royalty Pharma's revenue streams by adding a significant royalty interest in a successful drug, potentially increasing its financial stability and growth prospects.

Risk Assessment

Risk Level: medium — The value of the royalty stream is dependent on the continued success and market penetration of Tremfya, which carries inherent market and regulatory risks.

Key Numbers

• $500.0M — Upfront Payment (Paid by Royalty Pharma for future royalty rights on Tremfya.)
• $50.0M — Potential Milestone Payments (Additional payments contingent on future events related to Tremfya.)

Key Players & Entities

• Royalty Pharma plc (company) — Registrant
• Johnson & Johnson (company) — Seller of royalty rights
• Tremfya (guselkumab) (drug) — Asset being acquired royalty rights for
• $500 million (dollar_amount) — Upfront payment for royalty rights
• $50 million (dollar_amount) — Potential milestone payments
• June 17, 2024 (date) — Closing date of the transaction

FAQ

Key Financial Figures

• $0.0001 — red Class A Ordinary Shares, par value $0.0001 per share RPRX The Nasdaq Stock Mar
• $242 million — ma" or the "Company") for approximately $242 million upfront. This option arose from the Evr
• $1.6 billion — sales of approximately CHF 1.4 billion ($1.6 billion), an increase of 39% at constant exchan
• $250 million — e Evrysdi royalty to Royalty Pharma for $250 million less royalties received. Royalty Tran
• $650m — Total (June 2024) Funding amount $650m upfront $1.0bn upfront $250m upfron
• $1.0b — 024) Funding amount $650m upfront $1.0bn upfront $250m upfront $1.9bn upfro
• $250m — mount $650m upfront $1.0bn upfront $250m upfront $1.9bn upfront (up to $250m
• $1.9b — ront $1.0bn upfront $250m upfront $1.9bn upfront (up to $250m option) Royalty
• $500m — p (on worldwide net sales) 3.4% up to $500m 4.7% on $500m-$1.0bn 6.0% on $1.0-$2.
• $1.0 — to $500m 4.7% on $500m-$1.0bn 6.0% on $1.0-$2.0bn 6.9% >$2.0bn 3.0% up to $500m
• $2.0b — 00m 4.7% on $500m-$1.0bn 6.0% on $1.0-$2.0bn 6.9% >$2.0bn 3.0% up to $500m 4.2%
• $1.3b — ase when aggregate royalties paid equal $1.3bn PTC may sell remaining royalty to Ro

Filing Documents

• d724682d8k.htm (8-K) — 37KB
• 0001193125-24-164004.txt ( ) — 155KB
• rprx-20240617.xsd (EX-101.SCH) — 3KB
• rprx-20240617_lab.xml (EX-101.LAB) — 17KB
• rprx-20240617_pre.xml (EX-101.PRE) — 11KB
• d724682d8k_htm.xml (XML) — 3KB

Forward-Looking Statements

Forward-Looking Statements The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this Form 8-K unless stated otherwise, and neither the delivery of this Form 8-K at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This Form 8-K contains statements that constitute "forward-looking statements" as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the Company's opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of our strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "target," "forecast," "guidance," "goal," "predicts," "project," "potential" or "continue," the negative of these terms or similar expressions. Forward-looking statements are based on management's current beliefs and assumptions and on information currently available to the Company. However, these forward-looking statements are not a guarantee of our performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of th

SIGNATURES

SIGNATURES Pursuant to the requirement of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ROYALTY PHARMA PLC Date: June 20, 2024 By: /s/ Terrance Coyne Terrance Coyne Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR